Crossmark

Outcomes Following Adalimumab Bio-originator to Biosimilar Switch—A Comparison Using Real-world Patient- and Physician-Reported Data in European Countries

Crossref DOI link: https://doi.org/10.1007/s40744-022-00526-w

Published Online: 2023-01-12

Published Print: 2023-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Taylor, Peter C. https://orcid.org/0000-0001-7766-6167
Gonzalez, Yuri Sanchez https://orcid.org/0000-0001-7261-1933
Clark, Ryan https://orcid.org/0000-0001-8877-6652
Faccin, Freddy https://orcid.org/0000-0002-3535-7152
Howell, Oliver https://orcid.org/0000-0002-2242-8054
Funding

Funding for this research was provided by:

AbbVie
License Information

Text and Data Mining valid from 2023-01-12

Version of Record valid from 2023-01-12
More Information

Article History

Received: 11 October 2022

Accepted: 24 November 2022

First Online: 12 January 2023